Search Results

Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted a patent claiming methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy.

At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active professionals can take interdisciplinary, career-oriented programs designed to help launch their careers and take them to the next level.

TVAX Biomedical (TVAX), is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. TVAX Immunotherapy® could fundamentally change the way cancer is treated as T cells can kill all cancer cells, including cancer stem cells, without the toxicity of current treatments. With early

Clearside Biomedical, Inc. announced that multiple oral presentations were delivered at the Clinical Trials at the Summit Meeting on June 8, 2024 in Park City, Utah.